Trials / Completed
CompletedNCT02163889
Serial Therapeutic and Antifungal Monitoring Protocol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- T2 Biosystems · Industry
- Sex
- All
- Age
- 18 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture. This study will collect a T2clinical specimen and companion blood culture from patients who have exhibited a positive blood culture by gram stain for yeast, and who are receiving treatment with antifungal therapy.
Detailed description
One blood culture and one set of T2clinical specimens will be collected at specified intervals to monitor the clearance of Candida infection from the bloodstream. Each T2 result will be compared to the companion blood culture result. The comparison will determine if the presence of antifungal therapy inhibits blood culture and leads to an incidence of blood culture false negative test results. The T2 result, which is not impacted by the presence of antifungal therapy, can show that the pathogen is still present for some additional period of time.
Conditions
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2014-06-16
- Last updated
- 2018-08-20
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02163889. Inclusion in this directory is not an endorsement.